Phase I trial of SBRT to the prostate fossa following prostatectomy

This Phase I trial evaluated the tolerability of moderate to extreme hypofractionation to the prostate fossa (PF), as measured by physician-scored toxicity and patient-reported outcomes. Given the similar EQD2 of all dose levels, we hypothesized that PF-SBRT would be well tolerated with toxicity comparable to standard fractionation. There was transient grade 2 rectal toxicity at all dose levels during and immediately following radiotherapy. We must await long-term follow-up to assess late toxicity.

http://bit.ly/2R5ibaT